Andrew Beardsley, MD
Hematology & Oncology · Asheville, NCNPI 1881855948
Payments from drug & device makers
Across 174 payments — averaging $4900.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$577K
- AstraZeneca$108K
- Regeneron$74K
- E.r. Squibb & Sons, L.L.C.$66K
- Beigene, Ltd.$26K
- Johnson & Johnson$298
- plus $2K from 34 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $576,764 |
| AstraZeneca(2 entities) | 15 | $107,806 |
| Regeneron | 36 | $74,457 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65,867 |
| Beigene, Ltd. | 13 | $25,970 |
| Johnson & Johnson | 17 | $298 |
| Medtronic | 1 | $157 |
| Pfizer | 10 | $156 |
| Incyte Corporation | 3 | $142 |
| Merck | 7 | $140 |
| AbbVie | 5 | $94 |
| GSK | 3 | $63 |
| Array Biopharma Inc | 3 | $62 |
| Mirati Therapeutics, Inc. | 2 | $51 |
| Seagen Inc. | 2 | $49 |
| Kyowa Kirin, Inc. | 3 | $45 |
| Beone Medicines USA, Inc. | 2 | $43 |
| Bayer | 2 | $42 |
| Eisai Inc. | 2 | $40 |
| Legend Biotech USA Inc. | 1 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Boehringer Ingelheim | 2 | $37 |
| Dendreon Pharmaceuticals LLC | 1 | $33 |
| Myriad Genetic Laboratories, Inc. | 2 | $31 |
| Ipsen Biopharmaceuticals, Inc | 2 | $28 |
| Astellas Pharma US Inc | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Bristol Myers Squibb | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Genmab U.S., Inc. | 1 | $21 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| Acrotech Biopharma Inc. | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $20 |
| Syndax Pharmaceuticals, Inc. | 1 | $19 |
| AVEO Pharmaceuticals, Inc. | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $18 |
| Adaptive Biotechnologies Corporation | 1 | $17 |
| Epizyme, Inc. | 1 | $14 |
| Spectrum Pharmaceuticals Inc. | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
$852,743 in reported general payments places this provider in the 85th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Asheville
- Christopher ChayAsheville$1.5M
- John PowderlyHuntersville$21.2M
- Kimberly BlackwellDurham$13.2M
- Joshua ZeidnerChapel Hill$11.2M
- Shelbi AtrashCharlotte$9.5M
- Matthew WieduwiltWinston Salem$9.5M
- Danielle BranderDurham$8.6M
- Jared WeissChapel Hill$7.3M
- Michael MorseDurham$6M
- Autumn McReeChapel Hill$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.